Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
COO 
The Cooper Companies, Inc (COO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: COO (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $90.88
1 Year Target Price $90.88
| 9 | Strong Buy |
| 2 | Buy |
| 8 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 23.32% | Avg. Invested days 42 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 16.53B USD | Price to earnings Ratio 44.45 | 1Y Target Price 90.88 |
Price to earnings Ratio 44.45 | 1Y Target Price 90.88 | ||
Volume (30-day avg) 19 | Beta 1.03 | 52 Weeks Range 61.77 - 100.24 | Updated Date 01/8/2026 |
52 Weeks Range 61.77 - 100.24 | Updated Date 01/8/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.87 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 9.16% | Operating Margin (TTM) 13.54% |
Management Effectiveness
Return on Assets (TTM) 3.47% | Return on Equity (TTM) 4.59% |
Valuation
Trailing PE 44.45 | Forward PE 18.66 | Enterprise Value 18837256381 | Price to Sales(TTM) 4.04 |
Enterprise Value 18837256381 | Price to Sales(TTM) 4.04 | ||
Enterprise Value to Revenue 4.6 | Enterprise Value to EBITDA 18.05 | Shares Outstanding 195978026 | Shares Floating 194565024 |
Shares Outstanding 195978026 | Shares Floating 194565024 | ||
Percent Insiders 0.62 | Percent Institutions 106.8 |
Upturn AI SWOT
The Cooper Companies, Inc
Company Overview
History and Background
The Cooper Companies, Inc. was founded in 1958 by Harry J. Cooper Sr. It initially began as a contact lens manufacturer and distributor. Over the decades, Cooper has strategically diversified and expanded its operations through organic growth and acquisitions, evolving into a global leader in vision care and reproductive and women's health. Key milestones include the establishment of CooperVision and the acquisition of a significant portfolio of women's health products.
Core Business Areas
- CooperVision: CooperVision is a global leader in the contact lens market, manufacturing and marketing a wide range of soft contact lenses for vision correction. This includes daily disposable, toric, multifocal, and colored lenses.
- CooperSurgical: CooperSurgical is a significant player in the medical device industry, focusing on reproductive and women's health. Its product portfolio includes devices for fertility, diagnostics, minimally invasive surgery, and office-based procedures, as well as contraceptives.
Leadership and Structure
The Cooper Companies, Inc. operates with a corporate leadership team responsible for overall strategy and governance. The two primary business units, CooperVision and CooperSurgical, have their own dedicated leadership and operational structures, allowing for focused management and market responsiveness within their respective sectors. The company is structured to facilitate global reach and product development.
Top Products and Market Share
Key Offerings
- Avairau00ae Family of Lenses: A line of silicone hydrogel daily disposable contact lenses designed for comfort and breathability. Competitors include Alcon (Dailies Total1), Johnson & Johnson (ACUVUE OASYS 1-Day), and Bausch + Lomb (ULTRA ONE DAY). Specific market share data for this product line is proprietary but contributes significantly to CooperVision's overall share.
- MyDayu00ae Family of Lenses: Silicone hydrogel daily disposable lenses offering advanced comfort and visual clarity. Competitors are the same as for Avairau00ae. This product line is a key driver of CooperVision's daily disposable segment growth.
- Paragardu00ae IUD: A non-hormonal intrauterine device (IUD) for long-acting reversible contraception. CooperSurgical acquired this product and it is a leading player in the long-acting reversible contraception market. Key competitors include Bayer (Mirena, Kyleena) and Teva Pharmaceuticals (Liq***).
- Leep Devices and Endometrial Sampling: A range of products used in gynecological procedures for diagnostics and treatment of cervical conditions and uterine abnormalities. Competitors include various medical device manufacturers specializing in women's health.
Market Dynamics
Industry Overview
The Cooper Companies operates in two primary, robust markets: the global contact lens industry and the specialized medical devices market for reproductive and women's health. The contact lens market is characterized by increasing adoption of daily disposables, growing demand in emerging markets, and advancements in lens technology. The women's health market is driven by an aging global population, increasing awareness of women's health issues, and a growing demand for advanced diagnostic and treatment solutions.
Positioning
The Cooper Companies is positioned as a leader in both its core segments. In contact lenses, CooperVision is a top global player known for innovation, particularly in silicone hydrogel technology and specialty lenses. In women's health, CooperSurgical is a significant provider of essential medical devices and diagnostics, with a strong portfolio of established brands and a focus on solutions for fertility and surgical procedures.
Total Addressable Market (TAM)
The global contact lens market is valued in the tens of billions of dollars and is projected to continue growing. The global women's health market, encompassing devices, diagnostics, and pharmaceuticals, is also a multi-billion dollar market with substantial growth potential. The Cooper Companies holds a significant share within its specialized niches of these large TAMs, particularly in specific segments like silicone hydrogel lenses and certain women's health devices. Its strategy involves capturing a larger share through product innovation, market penetration in underserved regions, and strategic acquisitions.
Upturn SWOT Analysis
Strengths
- Strong brand recognition and established market presence in both CooperVision and CooperSurgical.
- Diverse product portfolio addressing key needs in vision correction and women's health.
- Commitment to research and development, leading to innovative product offerings.
- Global distribution network and established customer relationships.
- History of successful strategic acquisitions to expand market reach and product lines.
Weaknesses
- Reliance on a limited number of core product categories within each segment.
- Potential vulnerability to shifts in healthcare regulations and reimbursement policies.
- Competition from larger, more diversified healthcare conglomerates.
- Integration challenges associated with past and future acquisitions.
Opportunities
- Growing demand for daily disposable contact lenses globally.
- Expansion into emerging markets for both contact lenses and women's health products.
- Development of new technologies and products in the fertility and diagnostic spaces.
- Increasing focus on preventative healthcare and early disease detection in women's health.
- Leveraging digital health solutions to enhance patient engagement and product delivery.
Threats
- Intensifying competition from both established players and new entrants.
- Potential for disruptive technological advancements from competitors.
- Economic downturns impacting consumer discretionary spending on vision care.
- Supply chain disruptions and raw material cost fluctuations.
- Increased regulatory scrutiny and potential for product recalls.
Competitors and Market Share
Key Competitors
- Alcon Inc. (ALC)
- Johnson & Johnson (JNJ)
- Bausch Health Companies Inc. (BHC)
Competitive Landscape
The Cooper Companies faces intense competition from large, diversified healthcare companies like Johnson & Johnson and Alcon, which have significant resources and broad market reach. While CooperVision is a major player, it competes for market share in specific contact lens segments. In women's health, CooperSurgical competes with a variety of specialized medical device manufacturers. Cooper's competitive advantage lies in its focused expertise within its chosen segments, agility, and a strong track record of innovation and successful acquisitions.
Major Acquisitions
Paragardu00ae IUD
- Year: 2017
- Acquisition Price (USD millions): 336
- Strategic Rationale: This acquisition significantly expanded CooperSurgical's portfolio in the long-acting reversible contraception market, a key growth area in women's health, and strengthened its position as a leader in reproductive health solutions.
Momentum Medical
- Year: 2021
- Acquisition Price (USD millions):
- Strategic Rationale: This acquisition enhanced CooperSurgical's offerings in gynecological diagnostics and minimally invasive surgical instruments, further solidifying its presence in the surgical and office-based procedure segments.
Growth Trajectory and Initiatives
Historical Growth: The Cooper Companies has demonstrated consistent historical growth, fueled by its leadership in the contact lens market and its strategic expansion into women's health. Acquisitions have played a significant role in accelerating this growth, allowing the company to enter new markets and broaden its product offerings. Organic growth has also been a steady contributor, driven by product innovation and market penetration.
Future Projections: Analyst projections for The Cooper Companies, Inc. typically indicate continued, solid growth. Forecasts often highlight the ongoing demand for their core products, the potential for expansion in emerging markets, and the successful integration of past and future acquisitions. The company is expected to maintain its trajectory of revenue and earnings growth, supported by its strong market positions.
Recent Initiatives: Recent strategic initiatives likely include continued investment in R&D for next-generation contact lenses, expansion of the CooperSurgical product portfolio through targeted acquisitions, and efforts to increase market share in key geographic regions, particularly in Asia-Pacific and other growing markets. The company also focuses on operational efficiencies and enhancing its digital presence.
Summary
The Cooper Companies, Inc. is a robust and strategically diversified healthcare company with strong positions in both contact lenses (CooperVision) and women's health (CooperSurgical). Its consistent financial performance, driven by innovation and strategic acquisitions, positions it well for future growth. Key strengths include its focused product portfolios and global reach, while potential challenges lie in intense competition and evolving regulatory landscapes. Continued investment in R&D and market expansion will be crucial for sustaining its success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- The Cooper Companies, Inc. Investor Relations
- Company Annual Reports (10-K filings)
- Financial News Outlets (e.g., Bloomberg, Reuters)
- Market Research Reports (e.g., Statista, Grand View Research - for industry trends and TAM)
Disclaimers:
This JSON output is based on publicly available information and general market analysis. Specific financial data points, market share percentages, and acquisition prices are estimates or illustrative examples where precise figures are proprietary or unavailable. This information is for informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About The Cooper Companies, Inc
Exchange NASDAQ | Headquaters San Ramon, CA, United States | ||
IPO Launch date 1983-12-30 | President, CEO & Non-Independent Director Mr. Albert G. White III | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 15000 | Website https://www.coopercos.com |
Full time employees 15000 | Website https://www.coopercos.com | ||
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.